Global Biologic Medication in COVID-19 Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI12240741

Publication Date:

December 3, 2024

Pages:

110

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Biologic Medication in COVID-19 market size was valued at US$ million in 2023. With growing demand in downstream market, the Biologic Medication in COVID-19 is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Biologic Medication in COVID-19 market. Biologic Medication in COVID-19 are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Biologic Medication in COVID-19. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Biologic Medication in COVID-19 market.
According to China's clinical trials of COVID-19 treatment, the number of chemical drugs accounted for the highest proportion, followed by biological drugs, cell therapy, vaccines, and traditional Chinese medicine. Among the biological drugs, IL-6 related monoclonal antibodies (anti-inflammatory) account for the largest proportion, including tocilizumab and Sarilumab. This report focuses on the investigation and analysis of biologic medication and predicts the future market development of biopharmaceuticals under the influence of COVID-19. Biological drugs are mainly divided into two categories: neutralizing antibodies and anti-inflammatory drugs. The main subdivisions include: IL-6, C5a, CD147, PD-1 and Interferon (beta-1a), etc.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Biologic Medication in COVID-19 market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Biologic Medication in COVID-19 market. It may include historical data, market segmentation by Type (e.g., Neutralizing Antibodies, Anti-inflammatory Drugs), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Biologic Medication in COVID-19 market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Biologic Medication in COVID-19 market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Biologic Medication in COVID-19 industry. This include advancements in Biologic Medication in COVID-19 technology, Biologic Medication in COVID-19 new entrants, Biologic Medication in COVID-19 new investment, and other innovations that are shaping the future of Biologic Medication in COVID-19.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Biologic Medication in COVID-19 market. It includes factors influencing customer ' purchasing decisions, preferences for Biologic Medication in COVID-19 product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Biologic Medication in COVID-19 market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Biologic Medication in COVID-19 market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Biologic Medication in COVID-19 market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Biologic Medication in COVID-19 industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Biologic Medication in COVID-19 market.
Market Segmentation:
Biologic Medication in COVID-19 market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Neutralizing Antibodies
Anti-inflammatory Drugs
Segmentation by application
COVID-19
Influenza
Malaria
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Sanofi
Novartis
Merck
Bayer
Shutaishen
Biogen
Regeneron Pharmaceuticals
Vir Biotech
Junshi Biosciences
Anke Biotechnology
OncoImmune

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Biologic Medication in COVID-19 Market Size 2019-2030
2.1.2 Biologic Medication in COVID-19 Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Biologic Medication in COVID-19 Segment by Type
2.2.1 Neutralizing Antibodies
2.2.2 Anti-inflammatory Drugs
2.3 Biologic Medication in COVID-19 Market Size by Type
2.3.1 Biologic Medication in COVID-19 Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Biologic Medication in COVID-19 Market Size Market Share by Type (2019-2024)
2.4 Biologic Medication in COVID-19 Segment by Application
2.4.1 COVID-19
2.4.2 Influenza
2.4.3 Malaria
2.4.4 Others
2.5 Biologic Medication in COVID-19 Market Size by Application
2.5.1 Biologic Medication in COVID-19 Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Biologic Medication in COVID-19 Market Size Market Share by Application (2019-2024)
3 Biologic Medication in COVID-19 Market Size by Player
3.1 Biologic Medication in COVID-19 Market Size Market Share by Players
3.1.1 Global Biologic Medication in COVID-19 Revenue by Players (2019-2024)
3.1.2 Global Biologic Medication in COVID-19 Revenue Market Share by Players (2019-2024)
3.2 Global Biologic Medication in COVID-19 Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Biologic Medication in COVID-19 by Regions
4.1 Biologic Medication in COVID-19 Market Size by Regions (2019-2024)
4.2 Americas Biologic Medication in COVID-19 Market Size Growth (2019-2024)
4.3 APAC Biologic Medication in COVID-19 Market Size Growth (2019-2024)
4.4 Europe Biologic Medication in COVID-19 Market Size Growth (2019-2024)
4.5 Middle East & Africa Biologic Medication in COVID-19 Market Size Growth (2019-2024)
5 Americas
5.1 Americas Biologic Medication in COVID-19 Market Size by Country (2019-2024)
5.2 Americas Biologic Medication in COVID-19 Market Size by Type (2019-2024)
5.3 Americas Biologic Medication in COVID-19 Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biologic Medication in COVID-19 Market Size by Region (2019-2024)
6.2 APAC Biologic Medication in COVID-19 Market Size by Type (2019-2024)
6.3 APAC Biologic Medication in COVID-19 Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Biologic Medication in COVID-19 by Country (2019-2024)
7.2 Europe Biologic Medication in COVID-19 Market Size by Type (2019-2024)
7.3 Europe Biologic Medication in COVID-19 Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biologic Medication in COVID-19 by Region (2019-2024)
8.2 Middle East & Africa Biologic Medication in COVID-19 Market Size by Type (2019-2024)
8.3 Middle East & Africa Biologic Medication in COVID-19 Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Biologic Medication in COVID-19 Market Forecast
10.1 Global Biologic Medication in COVID-19 Forecast by Regions (2025-2030)
10.1.1 Global Biologic Medication in COVID-19 Forecast by Regions (2025-2030)
10.1.2 Americas Biologic Medication in COVID-19 Forecast
10.1.3 APAC Biologic Medication in COVID-19 Forecast
10.1.4 Europe Biologic Medication in COVID-19 Forecast
10.1.5 Middle East & Africa Biologic Medication in COVID-19 Forecast
10.2 Americas Biologic Medication in COVID-19 Forecast by Country (2025-2030)
10.2.1 United States Biologic Medication in COVID-19 Market Forecast
10.2.2 Canada Biologic Medication in COVID-19 Market Forecast
10.2.3 Mexico Biologic Medication in COVID-19 Market Forecast
10.2.4 Brazil Biologic Medication in COVID-19 Market Forecast
10.3 APAC Biologic Medication in COVID-19 Forecast by Region (2025-2030)
10.3.1 China Biologic Medication in COVID-19 Market Forecast
10.3.2 Japan Biologic Medication in COVID-19 Market Forecast
10.3.3 Korea Biologic Medication in COVID-19 Market Forecast
10.3.4 Southeast Asia Biologic Medication in COVID-19 Market Forecast
10.3.5 India Biologic Medication in COVID-19 Market Forecast
10.3.6 Australia Biologic Medication in COVID-19 Market Forecast
10.4 Europe Biologic Medication in COVID-19 Forecast by Country (2025-2030)
10.4.1 Germany Biologic Medication in COVID-19 Market Forecast
10.4.2 France Biologic Medication in COVID-19 Market Forecast
10.4.3 UK Biologic Medication in COVID-19 Market Forecast
10.4.4 Italy Biologic Medication in COVID-19 Market Forecast
10.4.5 Russia Biologic Medication in COVID-19 Market Forecast
10.5 Middle East & Africa Biologic Medication in COVID-19 Forecast by Region (2025-2030)
10.5.1 Egypt Biologic Medication in COVID-19 Market Forecast
10.5.2 South Africa Biologic Medication in COVID-19 Market Forecast
10.5.3 Israel Biologic Medication in COVID-19 Market Forecast
10.5.4 Turkey Biologic Medication in COVID-19 Market Forecast
10.5.5 GCC Countries Biologic Medication in COVID-19 Market Forecast
10.6 Global Biologic Medication in COVID-19 Forecast by Type (2025-2030)
10.7 Global Biologic Medication in COVID-19 Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Biologic Medication in COVID-19 Product Offered
11.1.3 Roche Biologic Medication in COVID-19 Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Sanofi
11.2.1 Sanofi Company Information
11.2.2 Sanofi Biologic Medication in COVID-19 Product Offered
11.2.3 Sanofi Biologic Medication in COVID-19 Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Sanofi Main Business Overview
11.2.5 Sanofi Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Biologic Medication in COVID-19 Product Offered
11.3.3 Novartis Biologic Medication in COVID-19 Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Merck
11.4.1 Merck Company Information
11.4.2 Merck Biologic Medication in COVID-19 Product Offered
11.4.3 Merck Biologic Medication in COVID-19 Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Merck Main Business Overview
11.4.5 Merck Latest Developments
11.5 Bayer
11.5.1 Bayer Company Information
11.5.2 Bayer Biologic Medication in COVID-19 Product Offered
11.5.3 Bayer Biologic Medication in COVID-19 Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Bayer Main Business Overview
11.5.5 Bayer Latest Developments
11.6 Shutaishen
11.6.1 Shutaishen Company Information
11.6.2 Shutaishen Biologic Medication in COVID-19 Product Offered
11.6.3 Shutaishen Biologic Medication in COVID-19 Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Shutaishen Main Business Overview
11.6.5 Shutaishen Latest Developments
11.7 Biogen
11.7.1 Biogen Company Information
11.7.2 Biogen Biologic Medication in COVID-19 Product Offered
11.7.3 Biogen Biologic Medication in COVID-19 Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Biogen Main Business Overview
11.7.5 Biogen Latest Developments
11.8 Regeneron Pharmaceuticals
11.8.1 Regeneron Pharmaceuticals Company Information
11.8.2 Regeneron Pharmaceuticals Biologic Medication in COVID-19 Product Offered
11.8.3 Regeneron Pharmaceuticals Biologic Medication in COVID-19 Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Regeneron Pharmaceuticals Main Business Overview
11.8.5 Regeneron Pharmaceuticals Latest Developments
11.9 Vir Biotech
11.9.1 Vir Biotech Company Information
11.9.2 Vir Biotech Biologic Medication in COVID-19 Product Offered
11.9.3 Vir Biotech Biologic Medication in COVID-19 Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Vir Biotech Main Business Overview
11.9.5 Vir Biotech Latest Developments
11.10 Junshi Biosciences
11.10.1 Junshi Biosciences Company Information
11.10.2 Junshi Biosciences Biologic Medication in COVID-19 Product Offered
11.10.3 Junshi Biosciences Biologic Medication in COVID-19 Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Junshi Biosciences Main Business Overview
11.10.5 Junshi Biosciences Latest Developments
11.11 Anke Biotechnology
11.11.1 Anke Biotechnology Company Information
11.11.2 Anke Biotechnology Biologic Medication in COVID-19 Product Offered
11.11.3 Anke Biotechnology Biologic Medication in COVID-19 Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Anke Biotechnology Main Business Overview
11.11.5 Anke Biotechnology Latest Developments
11.12 OncoImmune
11.12.1 OncoImmune Company Information
11.12.2 OncoImmune Biologic Medication in COVID-19 Product Offered
11.12.3 OncoImmune Biologic Medication in COVID-19 Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 OncoImmune Main Business Overview
11.12.5 OncoImmune Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂